Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (441-450 of 471) with videos related to

Pageof 48
Sort By:
Haematologica|February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2019
EANM procedure guidelines for radionuclide therapy with <sup>177</sup>Lu-labelled PSMA-ligands (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, et al.
Journal for Immunotherapy of Cancer|January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primaryAtara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
Journal of Neuroendocrinology|May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task forceAnna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Cancer Discovery|January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysisTiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical ImplementationRonald Boellaard, Irène Buvat, Christophe Nioche, et al.
Theranostics|October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancersAndrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
Journal of Medical Genetics|September 12, 2018
Bayesian approach to determining penetrance of pathogenic SDH variantsDiana E Benn, Ying Zhu, Katrina A Andrews, et al.
Journal of Neuroendocrinology|December 9, 2024
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task ForceVikas Prasad, Anna Koumarianou, Timm Denecke, et al.
Pageof 48

Showing results (441-450 of 471) with videos related to

Sort By:
Pageof 48
Haematologica|February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2019
EANM procedure guidelines for radionuclide therapy with <sup>177</sup>Lu-labelled PSMA-ligands (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang Peter Fendler, Matthias Eiber, et al.
Journal for Immunotherapy of Cancer|January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primaryAtara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
Journal of Neuroendocrinology|May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task forceAnna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Cancer Discovery|January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysisTiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline <sup>18</sup>F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical ImplementationRonald Boellaard, Irène Buvat, Christophe Nioche, et al.
Theranostics|October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancersAndrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
Journal of Medical Genetics|September 12, 2018
Bayesian approach to determining penetrance of pathogenic SDH variantsDiana E Benn, Ying Zhu, Katrina A Andrews, et al.
Journal of Neuroendocrinology|December 9, 2024
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task ForceVikas Prasad, Anna Koumarianou, Timm Denecke, et al.
Pageof 48